Shanghai RAAS Blood Products Co Ltd Class A - Asset Resilience Ratio

Latest as of December 2025: 2.03%

Shanghai RAAS Blood Products Co Ltd Class A (002252) has an Asset Resilience Ratio of 2.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥765.31 Million
≈ $111.99 Million USD Cash + Short-term Investments

Total Assets

CN¥37.78 Billion
≈ $5.53 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Asset Resilience Ratio has changed over time. Check 002252 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Shanghai RAAS Blood Products Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002252 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥765.31 Million 2.03%
Total Liquid Assets CN¥765.31 Million 2.03%

Asset Resilience Insights

  • Limited Liquidity: Shanghai RAAS Blood Products Co Ltd Class A maintains only 2.03% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai RAAS Blood Products Co Ltd Class A Industry Peers by Asset Resilience Ratio

Compare Shanghai RAAS Blood Products Co Ltd Class A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Immunitybio Inc
NASDAQ:IBRX
Biotechnology 38.07%
Sk Biopharmaceuticals Co Ltd
KO:326030
Biotechnology 0.14%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 23.94%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%
Zhejiang Shouxiangu Pharm Co
SHG:603896
Biotechnology 12.69%
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
Biotechnology 37.23%

Annual Asset Resilience Ratio for Shanghai RAAS Blood Products Co Ltd Class A (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai RAAS Blood Products Co Ltd Class A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 2.02% CN¥765.31 Million
≈ $111.99 Million
CN¥37.80 Billion
≈ $5.53 Billion
-2.86pp
2024-12-31 4.89% CN¥1.64 Billion
≈ $240.54 Million
CN¥33.63 Billion
≈ $4.92 Billion
+4.27pp
2023-12-31 0.62% CN¥197.41 Million
≈ $28.89 Million
CN¥31.93 Billion
≈ $4.67 Billion
-0.16pp
2022-12-31 0.78% CN¥237.77 Million
≈ $34.79 Million
CN¥30.46 Billion
≈ $4.46 Billion
-0.02pp
2021-12-31 0.81% CN¥219.38 Million
≈ $32.10 Million
CN¥27.24 Billion
≈ $3.99 Billion
-0.22pp
2020-12-31 1.03% CN¥262.14 Million
≈ $38.36 Million
CN¥25.49 Billion
≈ $3.73 Billion
-1.46pp
2019-12-31 2.49% CN¥295.40 Million
≈ $43.23 Million
CN¥11.85 Billion
≈ $1.73 Billion
-0.38pp
2018-12-31 2.87% CN¥327.05 Million
≈ $47.86 Million
CN¥11.40 Billion
≈ $1.67 Billion
-18.83pp
2017-12-31 21.70% CN¥3.14 Billion
≈ $458.95 Million
CN¥14.46 Billion
≈ $2.12 Billion
+5.39pp
2016-12-31 16.31% CN¥2.16 Billion
≈ $315.65 Million
CN¥13.23 Billion
≈ $1.94 Billion
+2.35pp
2015-12-31 13.96% CN¥1.61 Billion
≈ $236.05 Million
CN¥11.56 Billion
≈ $1.69 Billion
+13.94pp
2014-12-31 0.02% CN¥2.00 Million
≈ $292.66K
CN¥9.38 Billion
≈ $1.37 Billion
-6.32pp
2013-12-31 6.35% CN¥99.96 Million
≈ $14.63 Million
CN¥1.58 Billion
≈ $230.49 Million
--
pp = percentage points

About Shanghai RAAS Blood Products Co Ltd Class A

SHE:002252 China Biotechnology
Market Cap
$4.90 Billion
CN¥33.46 Billion CNY
Market Cap Rank
#3637 Global
#515 in China
Share Price
CN¥5.04
Change (1 day)
+2.86%
52-Week Range
CN¥4.31 - CN¥7.18
All Time High
CN¥24.72
About

Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more